CONSTELLA 72 MCG
LINACLOTIDE : 72 MCG · DIN 02469510 · ABBVIE CORPORATION
Health Canada status: MARKETED
What is CONSTELLA?
CONSTELLA 72 MCG contains LINACLOTIDE : 72 MCG. It is listed in the Health Canada Drug Product Database under DIN 02469510, held by ABBVIE CORPORATION, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 01-Aug-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CONSTELLA used for?
CONSTELLA (linaclotide capsules) is indicated for the treatment of: irritable bowel syndrome with constipation (IBS-C) in adults; chronic idiopathic constipation (CIC) in adults; functional constipation (FC) in pediatric patients 6 to 17 years of age.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02469510 |
|---|---|
| Brand name | CONSTELLA |
| Generic / active ingredient | LINACLOTIDE : 72 MCG |
| Manufacturer | ABBVIE CORPORATION |
| Strength | 72 MCG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A06AX04 LINACLOTIDE |
| AHFS class | 56:92.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 01-Aug-2024 |
| Original market date | 2018-04-02 00:00:00 |
How is it stored and handled?
null
How is it supplied?
Bottles of 30 capsules
What can be used instead?
Other Canadian products sharing ATC code A06AX04 LINACLOTIDE. 3 of 3 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CONSTELLA | 145 MCG | CAPSULE | ABBVIE CORPORATION | MARKETED | DIN 02417162 |
| CONSTELLA | 290 MCG | CAPSULE | ABBVIE CORPORATION | MARKETED | DIN 02417170 |
Who else supplies LINACLOTIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LINACLOTIDE appears in 6 registered pack listings across 4 markets, published on 3 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.